View our currently open positions.

Job listings brought to you by Rippling ATS.
Announcing the $15M Catalytic Fund. Together we can reach 5M mothers and babies by 2025!


Ending preventable newborn deaths from RDS.

Premature babies with Respiratory Distress Syndrome (RDS) have difficulty breathing, that if untreated results in 100% mortality. FlowLite, our nCPAP (neonatal continuous positive air pressure) device, will ensure high-quality newborn RDS treatment is within most countries' capacity to implement and save more newborn babies' lives.

How FlowLite Works

How FlowLite Works

Built-in Visual instructions:
LCD screen includes visual step-by-step for easy set-up and training

delivers safe and effective therapy to infant

Sensor technology:

alerts NICU staff when there is a problem in therapy delivery

Smart alarms:
adjustable volume alarms for troubleshooting issues

Back-up battery:
enables continued use in transportation and power outages

  • 1 in 10

    births is premature

  • 30%

    premature babies

    experience RDS

  • 20%

    mortality rate from RDS in India, compared to <2% in the US

  • 3.2M

    estimated number of cases our nCPAP could address each year

How nCPAP equalizes health outcomes?
  • Effective. Improves delivery of respiratory support to newborns.

  • Efficient. Enables overburdened referral hospitals to effectively manage and treat many babies at once.

  • Proactive. Sensor technology alerts nurses if a problem arises with the therapy, even if they are across the NICU.

  • Simple. Electronically humidifies, oxygenates, and pressurizes air flow, eliminating the need for external components.

  • Durable. Battery pack allows device to withstand power outages and emergency transport.

  • Portable. While still meeting world-class regulatory standards.